NEW YORK — Accenture
has entered into an agreement to acquire Octagon Research Solutions, Inc., a
provider of clinical and regulatory information management solutions and
software for the pharmaceutical industry. Terms of the transaction were not
acquisition will enhance Accenture''s ability to help its pharmaceutical clients
achieve more efficient global regulatory submissions that will enable them to
get medicines to market more quickly, safely and at a lower cost. Accenture''s capabilities will be expanded to
include comprehensive clinical and regulatory services - from clinical data
collection to regulatory submissions management. Accenture also will extend its business
process outsourcing (BPO) services portfolio targeting the pharmaceutical
380-member staff is said to have deep experience in clinical data services and
regulatory submissions, with 400 original applications completed, and the
company is the fifth largest user of the U.S. Food and Drug Administration''s
(FDA) electronic submission gateway.
Octagon is a recognized provider for the FDA in establishing clinical
data conversion and training standards and has deep knowledge of regulatory
affairs combined with well established relationships developed by partnering
with regulatory authorities. Octagon
will be fully integrated into Accenture''s Life Sciences industry group.
believe that the timing is perfect for this acquisition as our clients are
increasingly under pressure to reduce the drug development and approval
timelines to get products to market more quickly, safely and cost
effectively," said David Boath, North American managing director for
Accenture''s Life Sciences industry group.
"Our clients have an urgent need to focus resources on the
scientific breakthroughs and also to improve the efficiency of their clinical
and regulatory operations. Octagon''s capabilities and experience will enable
Accenture to provide comprehensive services spanning regulatory operations,
submissions management, clinical data conversion and clinical data management. The acquisition will enable Accenture to
offer what we view as the industry''s first comprehensive regulatory services
solution with a global footprint."